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Immunochemical studies of the Alport antigen. The Alport antigen, a
component of normal glomerular basement membranes (GBM) which is
absent in Alport familial nephntis, is characterized as a 26 kD non-
collagenous (NC!) peptide identified by a monoclonal antibody (Mab
A7) and an Alport alloantibody. Both antibodies discriminate X-linkage
of the Alport defect using indirect immunofluorescence of hemizygous
and heterozygous Alport GBM and epidermal basement membrane
(EBM). Immunoblotting of SDS-PAGE gels of collagenase-digested
Alport renal BM shows absence of monomeric and dimeric components
of the Alport antigen, a3(IV) NC!, and a4(IV) NC 1. By immunopre-
cipitation experiments with specific antibodies, the Alport antigen is
distinct from the 26 kD NC! peptide derived from al(IV). The mono-
clonal antibody to the Alport antigen and rabbit antiserum to a
non-consensus sequence of a5(IV) NC! react similarly by immunoflu-
orescence with normal kidney and both fail to bind to Alport renal BM.
Two dimension Western blots of collagenase-digested BM show that
the anti-Alport antigen and the ant-a5(IV) NC1 react similarly with
monomeric and dimeric components of BM collagen. These studies are
consistent with the likelihood that the Alport antigen and a5(IV) NC!
are the same or are highly homologous molecules. The precise relation-
ship will require characterization of a5(IV) NC 1 protein and determi-
nation of the nucleotide sequence of the Alport antigen. The associated
absence of s3(IV) NC! and a4(IV) (NC 1) from Alport BM is consistent
with other observations for a molecular association of these chains in a
novel collagen network.
Alport familial nephritis (FN) is a progressive renal disease
often accompanied by sensorineura! hearing !oss [1]. An anti-
body which was made by an Alport patient in response to a
normal renal al!ograft has been shown to react with normal
glomerular basement membrane (GBM) and epidermal base-
ment membrane (EBM) by immunofluorescence, but not to
bind to the GBM and EBM of affected X-linked dominant
Alport males [2, 3]. Further, this alloantibody is genetically
discriminated by staining the GBM [4] and EBM [2] of affected
female heterozygotes in a mosaic pattern consistent with ran-
dom inactivation of the X chromosome. Western b!otting of the
non-collagenous domain (NC!) of human GBM collagen shows
reactivity with a 26 kD peptide (Alport antigen).
Hostikka et al [5] and Myers et al [6] have sequenced cDNA
encoding the 3' end of an X-linked collagen gene with a
translated NC! domain which has 86% amino acid homology to
the NC! of cil(IV). The !ocation of the gene for this a5(IV)
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molecule on the long arm of the X chromosome (Xq22) suggests
that it is involved in Alport FN. The cDNA clone which was
used to analyze restriction digests of Alport genomic DNA
identified mutations in the c5(IV) gene in 3 of 18 families
studied [7]. One of these mutations, which resulted in an altered
Pst ! site, has been sequenced, revealing a cysteine to serine
shift resulting from a single base substitution [8]. The 3' half of
the gene has been characterized, and resembles al(IV) in its
intron/exon pattern [9]. An anti-peptide antibody made to a
non-consensus sequence of the derived aS(IV) protein se-
quence stained the GBM of norma! kidney [5]. Since very little
protein data is available for a5(IV), it has not been possib!e to
establish its relationship to the 26 kD Alport antigen identified
with the Alport al!oantibody [2].
Two recently described nove! 28 kD NC! peptides derived
from a3(IV) and a4(IV) [10, 1!] were not detected in collage-
nase digests of Alport GBM [28]. Monoclonal antibodies (Mab)
with specificity for monomeric and dimeric forms of these
peptides react by immunofluorescence with BM of normal
kidney, eye, lung, cochlea, and brain in a distribution which is
more restricted than that observed with antibodies to classical
type IV collagen [13, !4]. Antibodies to these novel chains do
not stain the GBM of affected Alport males although in some
patients granular reactivity may be observed in Bowman's
capsule. In the heterozygous female areas of GBM fluorescence
are interspersed with regions of negativity [4]. These two
peptides have been purified, and N-terminal amino acid se-
quences were shown to be unique but with regions of consensus
with al(IV) and a2(IV) [15, 16]. Recently, the eDNA sequence
of bovine a3(IV) NC! and a partial sequence of human a3(IV)
NC! have been determined [!0, !!].
a3(IV) NC! and a4(IV) NC! codistribute with the Alport
antigen in situ, but the latter is often present in BM such as
EBM in which the a3(IV) and a4(IV) NC! peptides are not
detected [13]. Indirect immunofluorescence of human feta!
kidney with antibodies to a3(IV), a4(IV), and the Alport
antigen shows an onset of gene expression later than that of
classical type IV collagen [17].
In the present study we describe a monoclonal antibody
reactive with the 26 kD Alport antigen and demonstrate that the
antigen is not detected in Alport GBM or EBM by immunohis-
tochemical techniques and Western blots of electrophoretically
separated components. Evidence is presented that this peptide
is distinct from the NC! monomer of a!(IV) chain, but is similar
to that of s5(IV).
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Table 1. Source and specificity of antibodies
Specificity Reference
Monoclonal antibody
Mab 85 a4(IV) NCI 13
Mab A2 a3(IV) NC1 19
Mab A7 Alport antigen Current report
Mab 102 al(LV) NC1 14
Mab 10 a(IV) NC! 19
Mab 14 al(IV) NC! 19
Mab 6 aI(IV) NCI 4, 13, 14
Polyclonal antibodies
Goat anti-type IV Pepsin-digested Southern
collagen human placenta!
BM
Biotechnologies
Human alloantibodies Alport antigen (26
kD)
2, 4
Anti-a5(IV) NC1 Peptide sequence of
cs5(IV) NCI
Current report
Methods
Tissue
Biopsies of skin from normal and Alport patients were
obtained as previously reported [2]. Normal and Alport kidney
and normal tissue sections used to confirm the specificity of a
monoclonal antibody to the Alport antigen (Mab A7) were
sectioned from a stored bank of tissues as previously described
[4]. Normal human kidneys, unsuitable for transplantation,
were acquired through the National Disease Research Inter-
change (NDRI), Philadelphia, PA. A kidney from a 12-year-old
male (E.T.) with Alport familial nephritis and kidneys from two
patients with diabetic nephropathy were obtained at the time of
pretransplantation nephrectomy. Fresh bovine kidneys were
procured from a local slaughterhouse. Tissues were dissected
and snap frozen in isopentane precooled in liquid nitrogen prior
to processing. This research was performed with the prior
approval of the University of Minnesota Committee on the Use
of Human Subjects in Research.
Immunohistochemistry.
Sections (3 to 4 jsm) prepared at constant temperature (23°C)
and humidity (30%) were air dried, fixed in 95% ethanol for five
minutes at 4°C, and rinsed three times with 0.01 M phosphate,
0.15 M NaC1, pH 7.2 (PBS) at room temperature. Sections were
denatured in a 0.1 M glycine, 6 M urea, pH 3.5 for one hour at
4°C, and then washed three times with PBS prior to reacting
with primary antibodies, as previously reported from this
laboratory [181.
Five of the seven Mabs were obtained following fusion of
NS 1 cells with spleen cells from immunized Balb/c mice (Table
1). Mab 102 was obtained from the fusion of rat spleen cells with
NS1 cells and Mab 6 was obtained from fusion of SP21O cells
with Balb/c spleen cells [15, 19]. Mab A7 (anti-Alport antigen)
was obtained by immunization of a Balb/c mouse with the
collagenase resistant residue of human GBM followed by fusion
of spleen cells with NS 1 cells. The Alport alloantibody was
obtained from an Alport patient with post-transplantation anti-
GBM nephritis as previously described [2—41. A rabbit anti-
a5(IV) NC! peptide antibody was made by immunizing rabbits
with a derived non-concensus amino acid sequence (VDVSD-
MFSKPQSE) linked to ovalbumin by m-maleimidobenzoyl-N-
hydroxysuccinamide ester. Serum was obtained prior to immu-
nization as a control.
Secondary antibodies were affinity purified fluorescein-con-
jugated and i-hodamine-conjugated goat [F(ab')2] anti-mouse
IgG, affinity purified fluorescein isothiocyanate(FITC)-conju-
gated swine anti-goat IgG, affinity purified FITC-conjugated
goat anti-rabbit IgG (Caltag, So. San Francisco, California,
USA) and affinity purified FITC-conjugated goat anti-rat IgG
(Organon/Tecknica-Cappel, Malvern, Pennsylvania, USA).
Dual fluorochrome immunofluorescence were carried out using
either one of two strategies: (1) Mab A7 detected with rho-
damine-conjugated rabbit anti-mouse IgG followed by the goat
antibody to type IV collagen (Southern Biotechnologies) which
was detected using mouse absorbed, FITC-conjugated, swine
anti-goat IgG or (2) Mab A7 detected with rhodamine-conju-
gated goat anti-mouse IgG (Caltag) followed by Mab 102
detected with FITC-conjugated goat anti-rat IgG. Similarly, the
anti-a5(IV) antibody was applied to the tissue and detected with
FITC-conjugated goat anti-rabbit IgG, followed by Mab A7,
detected with rhodamine-conjugated goat anti-mouse IgG. Ap-
propriate controls were used as previously described [13, 14,
17, 20]. All secondary antibodies were absorbed with human
serum to satisfy negative background reactivity with human
tissue. Slides were viewed under an epifluorescence micro-
scope with appropriate filters (Carl Zeiss, Thornwood, New
York, USA).
Biochemical and immunochemical techniques
isolation of human and bovine GBM. Normal human kidney
cortices, diabetic kidney, Alport kidney and fresh bovine renal
cortices were diced and homogenized in 0.15 M NaC1 using a
Brinkmann Polytron (Brinkmann Instruments Co., Westbury,
New York, USA) at setting 4.5. Glomeruli were retrieved by
size-selective sieving [21]. The normal and diabetic human
homogenates were first passed through a 35-mesh to remove
interstitium, followed by a 70-mesh to remove tubules, and
glomeruli were collected on a 230-mesh. The procedure for
retrieving bovine glomeruli was identical but the mesh sizes
were 35, 70, and 170, respectively. Alport glomeruli and tubules
were difficult to separate from each other and from interstitial
fibrils, and are representative of fractions which are GBM and
TBM in content. All solutions used in the isolation and extrac-
tion of the GBM contained the protease inhibitors 1 mri EDTA,
1 mM phenylmethylsulfonyl fluoride (PMSF), 1 m N-ethyl-
masleimide (NEM) and 1 m E-amino caproic acid. All stages
of the preparation were kept on ice.
Gloineruli were washed in PBS and disrupted by sonication in
1 M NaCl using 20 second bursts until whole glomeruli could not
be found in the solution. GBM was retrieved by centrifugation,
and washed extensively with PBS,
Extraction and enzyme digestion of GBM. The washed GBM
was extracted for 24 hours at 4°C using 0.5 M NaCI, PBS, with
protease inhibitors. Membranes were retrieved by centrifuga-
tion and a second 24 hour extraction in 0.5 54 NaCl, PBS was
performed. For isolation of NC1, the remaining membranes
were then extracted for 72 hours at 4°C using 3% acetic acid (10
sg/ml pepstatin A), retrieved by centrifugation, dialized and
lyophilized [12]. For isolation of NC! monomers and dimers,
the membranes were extracted for 48 hours in 6 M guanidine
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HC1, 0.05 M Tris, pH 7.4, retrieved by centrifugation, washed
extensively with 0.05 M Tris, 0.15 M NaC1, pH 7.4 (TBS), and
dialyzed into collagenase digestion buffer described below.
Extracted membranes were digested for 24 hours at 37°C with
type VII bacterial collagenase (Sigma Chemicals, St. Louis,
Missouri, USA) in 0.05 M Tris, 0.2 M NaCI, 0.002 M CaC12, pH
7.4 using 10 U/mg membranes as previously described [121. The
insoluble material was removed by centrifugation at 10,000 x g
and the soluble GBM fraction was concentrated by Amicon
filtration (Amicon, Danvers, Massachusetts, USA), and equili-
brated in 0.05 M Tris, 4 M urea, pH 7.4.
Chromatography. Collagenase-digested bovine, and normal,
diabetic and Alport human GBM were applied to Sepharose-Q
fast flow columns (PharmacialLKB, Piscataway, New Jersey,
USA) run in 0.5 M Tris, 4 M urea, pH 7.4. The unbound
fractions containing the NC 1 were pooled, dialized against
distilled water and lyophilized. The unbound fractions from the
Q sepharose columns of undenatured normal human GBM were
size separated on a Bio-Gel A-0.5m (Biorad, Richmond, Cali-
fornia, USA) column (1.5 x 120 cm) in TBS, 0.1 M CaCl2,
0.02% sodium azide, pH 7.4 as previously described [12]. The
poois containing NC! were dialyzed against three changes of
distilled water and lyophilized. The yield of collagenase di-
gested Alport and diabetic GBM and TBM was not large enough
to size separate the NC!.
Unbound fractions from Sepharose-Q columns of 6 M guani-
dine HCI denatured human and bovine GBM were separated
into monomer and dimer pools by gel filtration on an S300
column (2.5 x !00 cm) run in 6 M guanidine HC1, 0.05 M Tris,
pH 7.4 as described elsewhere [22]. Pools of monomers and
dimers were concentrated by evaporation and dialyzed into
TBS for immunoprecipitation experiments.
Gel electrophoresis. Forty micrograms of normal and dis-
eased NC1 was applied to each lane of an 8 to 18% SDS
polyacrylamide gel (PAGE) using a discontinuous buffer system
[23]. Gels were either stained with Coomassie blue or used for
immunoblotting. One hundred and fifty micrograms of human
GBM NC 1 was applied to non-equilibrium pH gradient gels
(NEPHGE) gels and electrophoresed as previously described
[12].
Immunobiotting. NC! proteins were electrophoretically
transferred from SDS-PAGE gels to 0.45 m Immobilon sheets
(Millipore Inc., Bedford, Massachusetts, USA) in a Biorad
vertical blotting apparatus using 40 V for six to eight hours as
previously described [24]. The transfers were blocked with !%
BSA in TBS for one hour at 37°C, and then reacted with mouse
or rat monoclonal antibodies for one hour at room temperature
[25]. Bound primary antibodies were detected by incubation
with alkaline phosphatase conjugated affinity-purified goat
F(ab')2 anti-mouse IgG (Caltag), alkaline phosphatase-conju-
gated goat anti-rabbit IgG, alkaline phosphatase conjugated
goat anti-rat IgG (Sigma Chemicals) followed by application of
alkaline phosphatase substrate BCIP/NBT (5-bromo-4-chloro-
3-indoyle phosphate/nitro blue tetrazoleum) (Promega Biotech,
Madison, Wisconsin, USA) in 0.1 M sodium carbonate, 0.001 M
MgCI2, pH 9.8.
Immunoprecipitation. Two hundred microliters of concen-
trated human NC! monomers were preabsorbed with 50 1d of
immuno-precipitin (formalin fixed Staph A cells) (BRL, Be-
thesda, Maryland, USA) which had been activated by centrif-
ugation and resuspension for !5 minutes in immuno-buffer (0.01
M Tris HCI, 0.14 M NaC!, 0.0025 M EDTA, 0.05% SDS, 0.5%
Na deoxycho!ate, 0.5% Triton X-!00 pH 7.6). Two hundred
microliters of monoclonal antibody supernatant or 50 jdof the
Alport alloantibody was added to the monomers retrieved by
centrifugation of the preabsorption mixture. Primary antibodies
were incubated with the antigen for two hours at 37°C, after
which 35 d of goat anti-mouse IgG1 or 50 d of goat anti-human
IgG were added to assist lattice formation. Secondary antibod-
ies were incubated with the primary reactions for one hour at
room temperature with gentle shaking. Two hundred microli-
ters of activated immuno-precipitin was added to the reaction
mixtures and allowed to react with the antibody complexes for
!5 minutes at 23°C. The suspensions were centrifuged and the
supernatant discarded. The immuno-precipitin pellet was
washed four times with immuno-buffer resuspended by vortex-
ing the centrifuged material. The washed pellets were solubi-
lized in 150 It! SDS sample buffer and applied to SDS-PAGE
gels using 30 It! per lane.
Results
Immunohistochemistry
Skin biopsies from 17 members of four families with X-linked
Alport familial nephritis who had been studied previously with
the human Alport a!loantibody [2, 3], and an additional family
not previously reported, were stained with Mab A7 (anti-Alport
antigen). Anti-type IV collagen antibodies, with polyclonal and
Mab 102, identified the EBM in all family members. Mab A7
identified the EBM on the same tissue sections of five normal
family members, did not react with the EBM of six affected
homozygous males, and showed segmental reactivity in six
affected females (Fig. 1). In a!! instances, staining was identical
to that previously reported for the human alloantibody [2].
Mab A7 stained the GBM, the TBM of distal nephron, and
Bowman's capsule of normal human kidney similar to the
staining pattern of the Alport a!loantibody whereas Mab 102
[anti-al(IV)] and polyclonal antibodies to type IV collagen
stained all renal basement membranes (Fig. 2). Mab A7 did not
stain Alport kidney. The distribution of reactivity of Mab A7 in
normal mature kidney, fetal kidney, and other tissues and the
absence of reactivity in A!port kidney was similar to that
previously reported using the Alport alloantibody [2, 4, 17].
Immunochemistry
Collagenase-digested normal human GBM, diabetic GBM
and TBM, and Alport GBM and TBM were electrophoresed in
8 to 18% SDS-PAGE gels and transferred to Immobilon by
Western blotting. Blots reacted with Mab A2 [a3(IV)], Mab 85
[a4(IV)], Mab A7 (Alport antigen) and Mab 14 [a!(IV) NC!]
resulted in the identification of al(IV) NC! monomers and
dimers in the Alport GBM and TBM but no detection of a3(IV)
NC!, a4(IV) NC 1, and 26 kD Alport antigen and related dimers
(Fig. 3). Normal human NC! and diabetic GBM and TBM show
the normal subunit distribution of a3(IV) NC!, a4(IV) NC!,
and the Alport antigen, as well as a!(IV) NC!.
Immunoprecipitation of NC1 monomers
Mab 14 [anti-a!(IV) NC!] and the Alport al!oantibody were
each used to precipitate human GBM NC! monomers using
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Fig. 1. The same denatured tissue sections of normal (A and B) and heterozygous (C and D) and hemizygous (E and F) Alport skin reacted
sequentially with Mab 102 (A, C, E) directed against the al(IV) NCI peptide and with Mab A7 (B, D, F) reactive with the A/port antigen. Note
the presence of both components in the EBM of normal skin (A and B) and the segmental loss of the Alport antigen (indicated by the 3 arrows)in heterozygous EBM (D) whereas normal reactivity is found in this EBM segment (the same arrows) with antibodies to al(IV) NCI (C). In
hemizygous skin, the EBM reacts with antibody to al(IV) NC1 (E) but not with antibody to the Alport antigen (F). In each photo, the epithelium
is to the right.
Immuno-precipitin (formalin fixed Staph A cells; Fig. 4). Each alloantibody precipitated a 26 kD monomer which reacted with
precipitate was blotted with Mab A7 (anti-Alport antigen) and Mab A7 (anti-Alport antigen) but did not react with Mab 10
Mab 10 [anti-a1(JV) NC!]. The results show that the Alport [anti-al(IV) NC1]. Conversely, the al(IV) Mab 14 precipitated
7? -
.9-. -
- --
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Fig. 2. The same tissue section of normal human kidney reacted sequentially with Mab A7 (anti-A/port) (A) and Mab 102 [anti-cr] (1 V) NCI] (B)
which identify the Alport antigen and the cvi (I V) NC) peptide, respectively. Note that the distribution of the Alport antigen is restricted to the GBM
and Bowman's capsule and not the mesangium (A). In contrast, the a! chain of type IV collagen is present in the mesangial matrix (arrow), along
the GBM, and all tubular and vascular BM (B). A phase contrast photomicrograph of the section (C) is shown for spatial clarity. By phase contrast
immunofluorescence the Alport antigen is superimposed on the lamina densa of the GBM whereas al(IV) is present in the subendothelial region
of the GBM in contiguity with the mesangial matrix.
Fig. 3. Immunoblotting of SDS-PAGE gels of collagenase-digested normal human GBM (lane 1), A/port GBM (lane 2), Alport TBM (lane 3),
diabetic GBM (lane 4) and diabetic TBM (lane 5) with anti-al (I V) NCJ (A), anti-M28[anti-a4(lV) NC]] (B), and anti-Alport antigen (C).
Monomers and dimers of all 5 preparations reacted with anti-al(IV). No monomer or dimer subunits of a4(IV) or the Alport antigen were detected
in Alport GBM or TBM (lanes 2 and 3, center and right panels). Mab A2 [anti-a3(LV) NC1] did not react with Alport GBM and TBM components
(not shown).
a 26 kD monomer which reacted with anti-crl(IV) Mab 10 but
which was not recognized by the anti-Alport antibody (Mab
A7). The Alport alloantibody was used in the precipitation
experiment because the monoclonal anti-Alport antibody does
not appear to recognize or precipitate the human antigen in
solution. This suggests that these two antibodies identify differ-
ent epitopes on the novel 26 kD peptide.
Relationship of cr5 (I V) to the 26 kD Alport antigen
The anti-a5(IV) NC 1 peptide antibody and Mab A7 (anti-
Alport) stain the same section of normal human kidney in a
similar distribution, colocalizing in the GBM, Bowman's cap-
sule and distal tubular basement membrane (Fig. 5). Absorption
of the anti-cv5(IV) antibody with the nonconsensus synthetic
1 4
4
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Fig. 4. Human NC] monomers from normal GBM were precipitated
with A/port alloantibodies (lanes 1) or Mab 14 [anti-al (I V) NCIJ (lanes
2), subjected to SDS-PAGE, and Western blots were then reacted with
Mab A7 (anti-A/port) (A) or Mab 10 [anti-cs] (I V) NC]] (B). Note that
the 26 kD monomer precipitated with Alport alloantibodies reacted with
Mab A7 (lane 1, A) but not with Mab 10 anti-a1(IV) NC1} (lane 1, B).
In contrast, the 26 kD monomer precipitated with anti-al(IV) NC1
reacted with Mab 10 (lane 2, B) and not with Mab A7 (lane 2, A).
peptide ablated all BM reactivity. Further, anti-a5(IV) peptide
did not stain Alport kidney. The distribution of fetal human
kidney was identical to that of the Alport antigen, with staining
of the primitive GBM, Bowman's capsule, distal TBM and the
ureteric bud but not the basement membranes of vesicles or S
forms [17].
Western blotting of human GBM NC 1 electrophoresed in two
dimensional NEPHGE gels showed reactivity of anti-a5(IV)
with bands similar to those reacting with Mab A7 (anti-Alport;
Fig. 6).
Discussion
In this report we show that a monoclonal antibody shares the
same genetically-discriminating specificity as a previously de-
Fig. 5. The same normal glomerulus stained with anti-a5(IV) NC]
peptide (A) and anti-A/port antigen (Mab A7) (B) showing identical
immunofluorescence. Alport kidney glomerulus does not stain with
anti-a5(IV) NC! (C).
scribed Alport alloantibody [21, reacting with a 26 kD NC 1
peptide distinct from al(IV) Nd. This Alport antigen and
a5(IV) NC! have similar characteristics when studied by im-
munofluorescence and Western blotting of two-dimensional
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Fig. 6. Two dimensional (SDS-PAGE and
NEPHGE) Western blots of NCI isolated
from normal human GBM and stained with
anti-A lport antigen (Mab A7) (A) and anti-
a5(IV) NCI peptide (B). Note the similarity in
monomeric subunits (26 kD) and the
homodimers of the same charge in A and B.
Importantly, several cationic dimers (pH>
9.0) are also present. The same cationic
dimers also stain with anti-a3(IV) NC1
indicating the presence of heterodimers (data
not shown). The arrows to the right of the
right panel denote a molecular weight of 54
kD.
NEPHGE gels. Neither is detected in Alport GBM. However
there is no conclusive proof at present that these peptides are
either identical or represent homologous but different mole-
cules. The associated absence of two other peptides, a3(IV)
NC1 and a4(IV) NC1 from Alport GBM supports the conten-
tion of a molecular association among these more recently
described collagen chains.
Our prior biochemical and immunochemical studies sug-
gested that the 26 kD component identified by the Alport
alloantibody was similar in charge and molecular weight to that
of al(IV) NCI [2]. This alloantibody reacted with NCI dimers
similar to those of al(IV), but in addition reacted with cationic
dimers of human NC 1 [261. The latter were not recognized by
antibodies to al(IV) [13]. Immunohistochemical studies of
Alport GBM and EBM have shown normal immunofluores-
cence using antibodies to al(IV) NC1, but no reactivity with the
Alport alloantibody in the hemizygote and segmental binding in
the heterozygote [2, 4]. These data had suggested an immuno-
chemical difference between the al(IV) peptide and the Alport
antigen, but there was no direct evidence to indicate that the
latter was either a uniquely modified version of the al(IV) NC1
or derived from a genetically-distinct collagen family. Since the
gene for al(IV) is located on chromosome 13 rather than the
X-chromosome [27], a modification of the al(IV) gene product
in Alport FN would have to originate on the X-chromosome.
Recently, the identification, by cDNA sequencing, of a collag-
enous X-linked gene product [a5(IV)} with a high degree ofNCl
homology to al(IV) and location at the Xq22 locus [5, 6]
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strongly suggested that it might be linked to the Alport FN
defect. Southern analysis of Alport genomic DNA demon-
strated mutations in the 3' end of this gene in three of 18 families
studied [7]. However, lack of essential protein characterization
of a5(IV) has prevented the critical linkage to the Alport antigen
identified with our genetically discriminating antibodies.
Acquisition of a monoclonal antibody (Mab A7) which dis-
criminates the X-linked inheritance of Alport familial nephritis
has resulted in the identification of the 26 kD Alport antigen
which is unrelated immunochemically to the 26 kD al(IV) NC!
peptide. Immunohistochemical analysis of normal and Alport
hemizygous and heterozygous skin biopsies not only confirms
the specificity of this antibody, but reaffirms previous data using
monoclonal antibodies specific for NC! peptide of al(IV) [2].
Furthermore, immunoprecipitation of human and bovine NC1
monomers and subsequent immunoblotting has demonstrated
the presence of two distinct 26 kD peptides: the Alport antigen
and the al(IV) NCI peptide.
The Alport antigen appears to be closely associated with the
a3(IV) NC1 and a4(IV) NC1 components previously described
[22, 28]. These peptides, like the Alport antigen, are absent
from the GBM of homozygous Alport patients by immunohis-
tochemical analysis, and the three antigens co-localize in a
segmental staining pattern in the GBM of heterozygous Alport
patients [4]. Here we have confirmed that all three antigens are
not detected in collagenase digests of Alport renal BM, though
classical type IV collagen with its normal al(IV) NCI subunit is
present as previously described [28]. The demonstration in
some Alport males that a3(IV) and a4(IV) are present in
Bowman's capsules and glomerular epithelial cells without
detectable Alport antigen suggests that the former peptides or
parent chains are not incorporated because the Alport antigen is
missing or defective [4]. The colocalization in normal kidney of
a5(IV) NC 1 and the Alport antigen and the absence of both in
Alport BM suggests that the two proteins become integrated
into the BM together, or that they are one and the same protein.
We hypothesize that the X-linked disorder in Alport familial
nephritis results in loss of the collagen chain from which the
Alport antigen is derived, Loss of this molecule prevents
normal integration of the parent collagen chains of a3(IV) and
a4(IV). Since classical type IV collagen does not appear to be
involved in the Alport defect nor closely associated morpho-
logically with these three novel chains, we suggest further that
the latter form an independent network of basement membrane
collagen, and that the entire network is defective in Alport
familial nephritis. Further support for the novel network is the
recent demonstration of striking differences in the expression of
these new components compared with al(IV) and a2(IV) in
studies of renal ontogeny [17], the spatial and temporal segre-
gation of these chains from l(IV) in diabetic nephropathy [29]
and membranous nephropathy [30], and the incorporation into
hexamers which do not contain classical type IV collagen [31].
Since intermolecular interaction in helices has been the
criteria for collagen chain nomenclature, the lack of evidence
supporting interactions between the classical chains of type IV
collagen and the novel chains of basement membrane collagen
suggests that the novel collagen network represents a distinct
type of collagen. However, recent nucleotide sequencing of
a3(IV) [10, 11] and aS(IV) [5, 6] indicates that the NC1 regions
of all type IV collagen molecules share amino acid homology
and are identical structurally with respect to the position of
cysteine residues. The latter lends strong support to the inclu-
sion of the novel collagen chains in the type IV family.
In this report, we have established that Mab A7 discriminates
with respect to the Alport phenotype and identifies the same 26
kD NC 1 peptide as the Alport alloantibody. Using Mab A7, we
have shown the Alport antigen to be absent from isolated Alport
GBM NC1 and to be distinct from the 26 kD al(IV) peptide. We
provide immunochemical evidence that Alport antigen and
a5(IV) NC 1 may be the same or homologous molecules; that
these codistribute in normal kidney but are absent from Alport
GBM; and that the antibodies to both components demonstrate
similar subunit reactivity in two-dimensional Western blots.
These criteria do not, however, constitute proof of identity. The
initial characterization of a5(IV) provided no protein-derived
data with respect to NC 1 [5] and the protein data presented
herein for the Alport antigen does not directly link it with the
nucleotide-derived data for a5(IV) NC 1. Future efforts will be
aimed at protein expression of an a5(IV) eDNA followed by
purification and immunoblotting with the anti-a5(IV) polyclonal
and Mab A7. The Alport phenotype has been linked to a
heterogeneous group of mutations on the a5(!V) [7, 8, 32].
Since the greater portion of Alport families do not appear to
have obvious a5(IV) mutations, we cannot rule out the pres-
ence of a second X-linked collagen chain, the Alport antigen,
which is also incorporated into the novel collagen network.
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